Navigation Links
Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment

COPENHAGEN, October 22 /PRNewswire-FirstCall/ -- Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX(R). For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment.

Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX(R), the company's tablet-based vaccine against grass pollen allergy. The clinical study documents that the effect of GRAZAX(R) persists following completion of the recommended three-year treatment regimen. Furthermore, blood samples from patients show a persistent, positive effect on the immune system indicating a lasting tolerance to grass pollen.

During the first year after completion of treatment, GRAZAX(R) continues to provide statistically significant reductions in both hay fever symptoms and the use of symptom-relieving medication.

In the follow-up year, hay fever symptoms were reduced by 31% while the use of symptom-relieving medication was reduced by 52%. The reduction of symptoms and use of medication is measured as median values relative to a control group in which patients had unrestricted access to symptom-relieving medication.

The patients in the study have adhered to the recommended three-year GRAZAX(R) treatment regimen and completed treatment in the autumn of 2007. The above-mentioned results cover the 2008 pollen season, the first season in which the patients did not receive active treatment with GRAZAX(R).

The fourth-year results represent a major breakthrough, since ALK is the first company ever to document a persistent disease modifying vaccination effect of a tablet-based allergy vaccine. Patients cannot obtain such a persistent vaccination effect with traditional symptom-relieving allergy medication.
ALK-Abelló A/S - Company release No 14/2008 - October 22, 2008

ALK-Abelló A/S

Jens Bager

President and CEO

For further information please contact:

Jens Bager, President and CEO, tel. +45-4575-7576

Investor Relations: Per Plotnikof, tel +45-4574-7527, mobile +45-2261-2525

Press: Jacob Frische, tel +45-4574-7551, mobile +45-2224-7551

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Phase III Trial Finds Pharmaxis Bronchitol Effective
3. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
4. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
5. New nanoparticle vaccine is more effective but less expensive
6. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem ... and aesthetics professionals from Central America and abroad for the first Iberoamerican Convention ... Panama Feb. 17-19, 2016. Testart will present and discuss new trends in anti-aging ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global ... Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group GMP ... a world-class team of qualified medical researchers and practitioners, experienced in administering stem ...
(Date:11/30/2015)... interventional radiology technique shows promise for helping morbidly obese patients ... being presented today at the annual meeting of the Radiological ... --> --> Gastric artery ... a way to stop bleeding in emergency situations, but the ... obesity is new. Mubin Syed , M.D., interventional ...
(Date:11/30/2015)... , December 1, 2015 Partnership includes an ... for the u niversity , ... support treatment s cale - up ... (ARVs)   Africa , where licensees based anywhere in the ... on SDN technology. --> Africa , where licensees based anywhere ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... November 17, 2015 Paris ... --> Paris from 17 th ... the biometrics innovation leader, has invented the first combined scanner ... the same scanning surface. Until now two different scanners were ... scanner can capture both on the same surface. This ...
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
Breaking Biology News(10 mins):